Kevin Moynihan, MD
Family Medicine · Lodi, CANPI 1982709028
Payments from drug & device makers
Across 232 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$772
- AstraZeneca$654
- Novo Nordisk$620
- Lilly USA, LLC$611
- GSK$469
- Boehringer Ingelheim$330
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,693100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 26 | $772 |
| AstraZeneca(2 entities) | 35 | $654 |
| Novo Nordisk | 36 | $620 |
| Lilly USA, LLC | 31 | $611 |
| GSK | 23 | $469 |
| Boehringer Ingelheim | 16 | $330 |
| Merck | 8 | $143 |
| Amgen(2 entities) | 8 | $138 |
| Bayer | 5 | $133 |
| Exact Sciences | 7 | $121 |
| Phathom Pharmaceuticals, Inc. | 6 | $101 |
| Johnson & Johnson(2 entities) | 5 | $94 |
| Novartis | 3 | $75 |
| Kowa Pharmaceuticals America, Inc. | 4 | $64 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Organogenesis Inc. | 2 | $41 |
| Vertex | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Medtronic | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| AbbVie | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Grifols USA, LLC | 1 | $17 |
| Intra-sana Laboratories | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Pfizer | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$4,693 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 259 | $266,124 |
| EliquisApixaban | 130 | $131,250 |
| JardianceEmpagliflozin | 76 | $87,485 |
| MounjaroTirzepatide | 74 | $77,379 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $65,616 |
| FarxigaDapagliflozin Propanediol | 66 | $63,318 |
| XareltoRivaroxaban | 48 | $54,012 |
| TrulicityDulaglutide | 49 | $52,636 |
| JanuviaSitagliptin Phosphate | 34 | $32,922 |
| EntrestoSacubitril/Valsartan | 16 | $26,564 |
| Dexlansoprazole DrDexlansoprazole | 34 | $13,865 |
| WegovySemaglutide | 11 | $12,787 |
| LinzessLinaclotide | 16 | $12,725 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 544 | $11,725 |
| Gabapentin | 332 | $9,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $620 | $278,911270 claims |
| PfizerEliquis | $16 | $131,250130 claims |
| Lilly USA, LLCMounjaro, Trulicity | $611 | $130,015123 claims |
| Boehringer IngelheimJardiance | $330 | $87,48576 claims |
| GSKTrelegy Ellipta | $469 | $65,61689 claims |
| AstraZenecaFarxiga | $654 | $63,31866 claims |
| Johnson & JohnsonXarelto | $94 | $54,01248 claims |
| MerckJanuvia | $143 | $32,92234 claims |
| NovartisEntresto | $75 | $26,56416 claims |
| AbbVieLinzess | $22 | $12,72516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Lodi
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.